Finance

Lists
MRCK34:BVMF
Merck BDR
97,04 BRL
0,00%
(0,00) 1D
4-сен., 17:06:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for MRCK34...
Open
96,50 BRL
High
97,04 BRL
Low
96,20 BRL
Mkt. cap
370,89 млд
Avg. vol.
3,73 миң
Volume
58,78 миң
52-wk high
101,38 BRL
52-wk low
51,06 BRL
Shares outstanding
2,47 млд
No. of employees
74 миң
Open
96,50 BRL
High
97,04 BRL
Low
96,20 BRL
Mkt. cap
370,89 млд
Avg. vol.
3,73 миң
Volume
58,78 миң
52-wk high
101,38 BRL
52-wk low
51,06 BRL
Shares outstanding
2,47 млд
No. of employees
74 миң
News stories
From web sources and news partners
Profile
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
About Merck BDR
CEORobert M Davis
Employees74 миң
Founded1891-ж., 1-янв.
Headquarters-
SectorPharmaceutical industry
Websitemerck.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
17,28 млд
16,40 млд
16,29 млд
16,61 млд
Cost of goods sold
3,74 млд
4,30 млд
3,88 млд
4,13 млд
Cost of revenue
3,74 млд
4,30 млд
3,88 млд
4,13 млд
Research and development expenses
4,00 млд
4,00 млд
3,56 млд
9,74 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,48 млд
2,73 млд
2,57 млд
2,78 млд
Operating expense
6,48 млд
6,73 млд
6,12 млд
12,52 млд
Total operating expenses
10,23 млд
11,02 млд
10,00 млд
16,65 млд
Operating income
7,05 млд
5,38 млд
6,29 млд
-40,00 млн
Other non operating income
-
41,00 млн
42,00 млн
59,00 млн
EBT including unusual items
6,74 млд
3,42 млд
-3,53 млд
-683,00 млн
EBT excluding unusual items
6,76 млд
4,98 млд
5,85 млд
-508,00 млн
Income tax expense
958,00 млн
458,00 млн
709,00 млн
654,00 млн
Effective tax rate
14,20%
13,39%
-20,06%
-95,75%
Other operating expenses
-
-
-
-
Net income
5,78 млд
2,96 млд
-4,24 млд
-1,34 млд
Net profit margin
33,49%
18,07%
-26,03%
-8,04%
Earnings per share
2,58
2,04
-1,28
-0,13
Interest and investment income
96,00 млн
69,00 млн
35,00 млн
35,00 млн
Interest expense
-327,00 млн
-411,00 млн
-479,00 млн
-525,00 млн
Net interest expenses
-231,00 млн
-342,00 млн
-444,00 млн
-490,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
8,15 млд
6,79 млд
7,69 млд
1,43 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору